Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins.
Le Gal F, Badur S, Hawajri NA, Akyüz F, Kaymakoglu S, Brichler S, Zoulim F, Gordien E, Gault E, Dény P.
Arch Virol. 2012 Apr;157(4):647-59. Epub 2012 Jan 13.
Related citations
Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
Lin KH, Hsu PI, Yu HC, Lin CK, Tsai WL, Chen WC, Chan HH, Lai KH.
BMC Gastroenterol. 2012 Jan 18;12:7.
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.
Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ.
Gastroenterology. 2012 Apr;142(4):978-88. Epub 2012 Jan 13.
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS.
Gastroenterology. 2012 Apr;142(4):790-5. Epub 2012 Jan 13.
Immune reactivity to β-tubulin isotype 5 and vesicular integral-membrane protein 36 in patients with autoimmune gastrointestinal disorders.
Op De Beéck K, Van den Bergh K, Vermeire S, Decock S, Derua R, Waelkens E, Rutgeerts P, Nevens F, Bossuyt X.
Gut. 2011 Nov;60(11):1601-2. Epub 2010 Dec 15. No abstract available.
High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis.
Pischke S, Gösling J, Engelmann I, Schlue J, Wölk B, Jäckel E, Meyer-Heithuis C, Lehmann U, Strassburg CP, Barg-Hock H, Becker T, Manns MP, Schulz T, Wedemeyer H, Heim A.
J Hepatol. 2012 May;56(5):1063-9. Epub 2012 Jan 13.
Understanding silibinin's modes of action against HCV using viral kinetic modeling.
Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS.
J Hepatol. 2012 May;56(5):1019-24. Epub 2012 Jan 13.
Case report: benefits of quantitative polymerase chain reaction in the clinical management of herpes simplex virus 1 infection with prominent hepatitis and unusual secondary progression.
Chaillon A, Schnepf N, Jonas M, Mondon K, Orain I, Lioger B, Cottier JP, Hommet C, Goudeau A.
J Med Virol. 2012 Mar;84(3):457-61. doi: 10.1002/jmv.23230.
Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China.
Shen L, Gu Y, Sun L, Yang Y, Wang F, Li Y, Bi S.
J Med Virol. 2012 Mar;84(3):445-9. doi: 10.1002/jmv.23212.
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.
J Med Virol. 2012 Mar;84(3):438-44. doi: 10.1002/jmv.23207.
Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
Chary A, Winters MA, Eisen R, Knight TH, Asmuth DM, Holodniy M.
J Med Virol. 2012 Mar;84(3):431-7. doi: 10.1002/jmv.23210.
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS.
J Med Virol. 2012 Mar;84(3):424-30. doi: 10.1002/jmv.23229.
Characterization of hepatitis B virus genome variability in Iranian patients with chronic infection, a nationwide study.
Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Damavand B, Azimzadeh P, Derakhshan F, Sabahi F, Zali MR.
J Med Virol. 2012 Mar;84(3):414-23. doi: 10.1002/jmv.23200.
New developments in HCV therapy.
Kronenberger B, Zeuzem S.
J Viral Hepat. 2012 Jan;19 Suppl 1:48-51. doi: 10.1111/j.1365-2893.2011.01526.x.
Steatosis and insulin resistance in response to treatment of chronic hepatitis C.
Negro F.
J Viral Hepat. 2012 Jan;19 Suppl 1:42-7. doi: 10.1111/j.1365-2893.2011.01523.x. Review.
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.
Rumi M, Aghemo A, Prati GM.
J Viral Hepat. 2012 Jan;19 Suppl 1:37-41. doi: 10.1111/j.1365-2893.2011.01525.x. Review.
How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?
Sebastiani G, Alberti A.
J Viral Hepat. 2012 Jan;19 Suppl 1:18-32. doi: 10.1111/j.1365-2893.2011.01518.x.
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Simón-Talero M, Buti M, Esteban R.
J Viral Hepat. 2012 Jan;19 Suppl 1:14-7. doi: 10.1111/j.1365-2893.2011.01521.x.
Optimal treatment duration for patients with HCV genotype 1 infection.
Ferenci P.
J Viral Hepat. 2012 Jan;19 Suppl 1:7-13. doi: 10.1111/j.1365-2893.2011.01522.x.
Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C.
Degasperi E, Aghemo A.
J Viral Hepat. 2012 Jan;19 Suppl 1:3-6. doi: 10.1111/j.1365-2893.2011.01517.x.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on